SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Orosz G.)
 

Search: WFRF:(Orosz G.) > (2008-2009) > Prognostic and pred...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Viale, Giuseppe (author)

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

  • Article/chapterEnglish2008

Publisher, publication year, extent ...

  • 2008

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/100421
  • https://gup.ub.gu.se/publication/100421URI
  • https://doi.org/10.1200/JCO.2008.17.0829DOI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • PURPOSE: To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy in postmenopausal women with early breast cancer. PATIENTS AND METHODS: Breast International Group (BIG) trial 1-98 randomly assigned 8,010 patients to four treatment arms comparing Let and Tam with sequences of each agent. Of 4,922 patients randomly assigned to receive 5 years of monotherapy with either agent, 2,685 had primary tumor material available for central pathology assessment of Ki-67 LI by immunohistochemistry and had tumors confirmed to express estrogen receptors after central review. The prognostic and predictive value of centrally measured Ki-67 LI on disease-free survival (DFS) were assessed among these patients using proportional hazards modeling, with Ki-67 LI values dichotomized at the median value of 11%. RESULTS: Higher values of Ki-67 LI were associated with adverse prognostic factors and with worse DFS (hazard ratio [HR; high:low] = 1.8; 95% CI, 1.4 to 2.3). The magnitude of the treatment benefit for Let versus Tam was greater among patients with high tumor Ki-67 LI (HR [Let:Tam] = 0.53; 95% CI, 0.39 to 0.72) than among patients with low tumor Ki-67 LI (HR [Let:Tam] = 0.81; 95% CI, 0.57 to 1.15; interaction P = .09). CONCLUSION: Ki-67 LI is confirmed as a prognostic factor in this study. High Ki-67 LI levels may identify a patient group that particularly benefits from initial Let adjuvant therapy.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Giobbie-Hurder, Anita (author)
  • Regan, Meredith M (author)
  • Coates, Alan S (author)
  • Mastropasqua, Mauro G (author)
  • Dell'Orto, Patrizia (author)
  • Maiorano, Eugenio (author)
  • MacGrogan, Gaëtan (author)
  • Braye, Stephen G (author)
  • Ohlschlegel, Christian (author)
  • Neven, Patrick (author)
  • Orosz, Zsolt (author)
  • Olszewski, Wojciech P (author)
  • Knox, Fiona (author)
  • Thürlimann, Beat (author)
  • Price, Karen N (author)
  • Castiglione-Gertsch, Monica (author)
  • Gelber, Richard D (author)
  • Gusterson, Barry A (author)
  • Goldhirsch, Aron (author)
  • Wallgren, Arne,1940Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences(Swepub:gu)xwalar (author)
  • Göteborgs universitetInstitutionen för kliniska vetenskaper (creator_code:org_t)

Related titles

  • In:Journal of clinical oncology : official journal of the American Society of Clinical Oncology26:34, s. 5569-751527-7755

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view